|
Product Info
|
|
Background |
The Neu/HER-2 (also known as EGFR-2 or ErbB-2) is a transmembrane tyrosine kinase receptor and a well-defined tumor antigen. Neu/HER-2 is a shared antigen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast, ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-existent immune response to Neu/HER-2 (1,2). Neu/HER-2 amplification/overexpression confers more aggressive and malignant characteristics on breast cancer cells. Patients with Neu/HER-2-amplified breast cancer have a worse prognosis than those with normal Neu/HER-2 expression (3).
|
|
Origin |
Neu (C18) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2).
|
|
Product Details |
Each vial contains 200 µg/ml of affinity purified rabbit IgG Neu (C18) DB049, in 1 ml PBS containing 0.1% sodium azide and 0.2% gelatin.
|
|
Competition Studies |
A blocking peptide is also available, DB049P, for use in competition studies. Each vial contains 0.100 mg of peptide in 0.5 ml PBS with 0.1% sodium azide and 100 mg BSA.
|
|
Form |
200 µg/ml of rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
|
|
Immunogen |
Synthetic peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2).
|
|
Specificity |
Neu (C18) DB049 reacts with Neu of mouse, rat, and human origin by western blotting, immunoprecipitation, and immunohistochemistry (including paraffin-embedded sections). Western blotting starting dilution: 1:200. SK-BR-3 lysates can be used as a positive control.
|
|
Use |
Western blot analysis of Neu expression in SK-BR-3 whole cell lysates.
|
|
Storage |
Store this product at 4º C, do not freeze. The product is stable for one year from the date of shipment.
|
|
References |
1. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Int J Endocr Relat Cancer 2002 Mar;9(1):33-44.
2. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001 Jul;2(2):129-35; discussion 136-7.
3. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001 Dec;28(6 Suppl 18):43-7
|
